<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662971</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-SFT-201704</org_study_id>
    <nct_id>NCT03662971</nct_id>
  </id_info>
  <brief_title>Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I Clinical Trial to Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal
      Peptide Eye Drops in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects enrolled in this study are healthy volunteers, divided into single dose groups
      and multiple doses groups with dose escalation.The study is designed to assign the subjects
      to five single-dose groups from low to high (0.0005%, 0.001%, 0.002%, 0.004% and 0.008%), and
      three multiple-dose groups (0.002%, 0.004% and 0.008%), with both male and female subjects in
      each group. This clinical trial is a double-blind design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">October 24, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ocular symptoms</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Ocular signs: conjunctival congestion, corneal epithelial injury, conjunctival edema, anterior chamber glow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve （0-t）</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>AUC（0-t）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve（0-∞）</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>AUC（0-∞）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentration</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak time</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>CL or CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>slit lamp examination</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Examination of cornea, conjunctiva, sclera, lens and vitreous body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fundus examination</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Observe the change of fundus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Observe the change of intraocular pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vision</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Observe the change of vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Observe the change of 12-lead ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Observe the occurrence and record of AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corneal fluorescein staining</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Observe the change of corneal fluorescein staining.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Corneal Defect</condition>
  <arm_group>
    <arm_group_label>0.0005% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.001% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.002% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.004% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.008% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.002% multiple-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.004% multiple-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.008% multiple-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Germinal peptide eye drops</intervention_name>
    <description>Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%</description>
    <arm_group_label>0.0005% single-dose</arm_group_label>
    <arm_group_label>0.001% single-dose</arm_group_label>
    <arm_group_label>0.002% multiple-dose</arm_group_label>
    <arm_group_label>0.002% single-dose</arm_group_label>
    <arm_group_label>0.004% multiple-dose</arm_group_label>
    <arm_group_label>0.004% single-dose</arm_group_label>
    <arm_group_label>0.008% multiple-dose</arm_group_label>
    <arm_group_label>0.008% single-dose</arm_group_label>
    <other_name>Germinal peptide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between 18 and 45, both male and female;

          2. The body mass index was between 19 and 26kg/m2 (including the critical value), the
             weight of male ≥50kg, and that of female ≥45kg；

          3. The BCVA of both eyes should be ≥ 1.0, and the intraocular pressure, slit lamp and
             fundus examination were all normal or abnormal values without clinical significance；

          4. Before the test, physical examination, vital signs, ECG, laboratory examination were
             in the normal range or no clinical significance；

          5. Women of childbearing age have negative blood pregnancy test, the subject should
             ensure that effective contraceptive measures are taken within 1 month before
             inclusion, and the subject (including male ) is willing to have no pregnancy plan in
             the next 6 months and voluntarily take effective contraceptive measures;

          6. Subjects volunteered to participate in the study and signed ICF.

        Exclusion Criteria:

          1. Patients with eye diseases, including a history of internal eye surgery or laser
             surgery;

          2. History of central nervous system, spirit system, cardiovascular system, kidney
             system, liver system, respiration system, metabolism and skeletal muscle system;

          3. Positive results of hepatitis B virus surface antigen (HBsAg), anti-hepatitis C virus
             (HCV) antibodies , syphilis spiral antibody (TP-Ab) or r anti-human immunodeficiency
             virus (HIV) antibodies;

          4. A significant clinical history of allergic reactions, especially drug allergies,
             especially allergic to any ingredient in Germinal peptide eye drops;

          5. Smoking more than 5 cigarettes a day on average;

          6. Suspicion or actual alcohol dependence; intake of more than 2 units of alcohol per day
             on average in 3 months (1 unit =10 mL ethanol,, 1 unit =200mL of beer or 25 mL of
             spirits with 40% alcohol or 83 mL of wine with 12% alcohol) or alcohol test positive;

          7. History of drug abuse, or a positive urine test of ketamine, morphine,
             methamphetamine, dimethylamine and tetrahydrocannabinoid;

          8. Take any medicine within 2 weeks before screening;

          9. Participated in clinical trials within 3 months before screening;

         10. Donation or loss of more than 400 ml of blood within 3 months before screening

         11. Used ophthalmic drugs or eyelash growth fluid within 2 weeks before screening;

         12. Used contact lenses or cosmetic contact lenses within 2 weeks before screening;

         13. Pregnant or lactating women and planned pregnancies (including male subjects);

         14. The researcher considers that it is not suitable for the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiuli Zhao</name>
      <address>
        <city>Beijing</city>
        <zip>BJ10</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

